An issue that remains concerns the identification of biomarkers for predicting the anticancer efficacy of ADCs, especially patritumab deruxtecan, whereas ongoing clinical trials will answer this question and clarify their advantages in patients with cancers resistant to EGFR-inhibitors. Here, EGFR is linked to cancer.